Patents Assigned to Upjohn
  • Publication number: 20020156275
    Abstract: The present invention are substituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (X) and unsubstituted 9-arylsulfone- 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (XI) such as the compound of EXAMPLE 13 1
    Type: Application
    Filed: October 30, 2001
    Publication date: October 24, 2002
    Applicant: Pharmacia and Upjohn Company
    Inventors: Eric Jon Jacobsen, Susan Fox Jacobsen
  • Publication number: 20020156585
    Abstract: The substrate free form of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB) has been crystallized, and the three dimensional x-ray crystal structure has been solved to 2.3 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of S. aureus MurB.
    Type: Application
    Filed: November 21, 2001
    Publication date: October 24, 2002
    Applicant: Pharmacia & Upjohn Company
    Inventor: Timothy E. Benson
  • Patent number: 6468999
    Abstract: The present invention are substituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (X) and unsubstituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (XI) such as the compound of EXAMPLE 13 which are useful in treating depression, obesity and other CNS disorders.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: October 22, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Eric Jon Jacobsen, Susan Korynne Hendges
  • Patent number: 6465458
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The methods comprise administering the optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: October 15, 2002
    Assignee: Pharmacia & UpJohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson, Pasquale Cetera
  • Patent number: 6462234
    Abstract: The present invention is a process, including intermediates, to produce (2S)-2-dipropylamino)-6-ethoxy-2,3-dihydro-1H-indene-5-carboxamide which is a useful pharmaceutical agent.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: October 8, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jiong Jack Chen, Arthur Glenn Romero, Styrbjorn Bystrom
  • Publication number: 20020143009
    Abstract: The present invention provides compounds of formula I useful as antimicrobial agents 1
    Type: Application
    Filed: March 4, 2002
    Publication date: October 3, 2002
    Applicant: Pharmacia & Upjohn
    Inventors: Michael J. Genin, Michael Robert Barbachyn, Jackson B. Hester, Paul D. Johnson
  • Patent number: 6458788
    Abstract: Certain novel 4-hydroxycinnoline-3-carboxyamides. The compounds are particularly effective in the treatment or prevention of viral infections, particularly infections caused by herpes viruses including herpes simplex virus types 1 and 2, human herpes virus types 6, 7 and 8, varicello zoster virus, human cytomegalovirus or Epstein-Barr virus.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: October 1, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Valerie A. Vaillancourt, Scott D. Larsen, Sajiv K. Nair
  • Patent number: 6458820
    Abstract: The present invention provides the use of pramipexole as a neuroprotective agent.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: October 1, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Edward Dallas Hall, Philip F. Von Voigtlander, Frank A. Rohde
  • Patent number: 6458768
    Abstract: Compounds which are benzoheterocyclic distamycin derivatives of formula (I), wherein n is 2, 3 or 4; A is a heteroatom selected from O and S or is a group NR, wherein R is hydrogen or C1-C4 alkyl; B is CH or N; R1 is hydrogen or C1-C4 alkyl; G is selected from the group consisting of (a, b, c, d, e, f, g, h, i, j), and —C≡N; wherein R5, R6, R7, R8, R9, R10, R11 and R12 are, independently from each other, hydrogen or C1-C4 alkyl; T is a group of formula (II) or (III) as defined above, wherein p is 0 or 1; R2 and R3 are, independently from each other, hydrogen, C1-C4 alkyl optionally substituted by one or more fluorine atoms, or C1-C4 alkoxy; R4 is C1-C4 alkyl or C1-C3 haloalkyl; X1 and X2 are halogen atoms or pharmaceutically acceptable salts thereof; provided that at least one of R5, R6 and R7 is alkyl; are useful as antitumor agents.
    Type: Grant
    Filed: September 19, 2000
    Date of Patent: October 1, 2002
    Assignee: Pharmacia & Upjohn, S.p.A.
    Inventors: Paolo Cozzi, Pier Giovanni Baraldi, Italo Beria, Marina Caldarelli, Laura Capolongo, Romeo Romagnoli
  • Patent number: 6455564
    Abstract: The present invention is a method of treating sexual disturbances in humans and inducing mating in non-human mammals using the compounds of formula (A) in a dosage range where the sexually therapeutic amount is from about 0.2 thru 8 mg/person/dose and where the sexually mating amount is from about 0.003 thru 0.2 mg/kg/dose.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: September 24, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Martin Durham Meglasson, Robert B. McCall
  • Patent number: 6455323
    Abstract: Staphylococcus aureus virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel S. aureus mutants useful in vaccines.
    Type: Grant
    Filed: July 3, 1997
    Date of Patent: September 24, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: David Holden, Ji Min Mei
  • Patent number: 6451838
    Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: September 17, 2002
    Assignee: Pharmacia & Upjohn company
    Inventors: Malcolm Wilson Moon, Walter Morozowich, Ping Gao
  • Patent number: 6452007
    Abstract: The present invention relates to two novel crystal forms of a known compound, 1-[5-Methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl] piperazine monomethanesulfonate salt, which are useful for treating humans who are HIV positive, which are identified by a powder X-ray diffraction spectrum known commonly as the “S” and “T” forms.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: September 17, 2002
  • Patent number: 6451811
    Abstract: The resent invention provides a compound of Formula III which is useful for the treatment or prevention of herpes viruses.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: September 17, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Valerie A. Vaillancourt, Atli Thorarensen
  • Publication number: 20020128475
    Abstract: The present invention are substituted 9-arylsulfone- 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles (X) and unsubstituted 9-arylsulfone- 1,2,3,4,5,6- hexahydroazepino[4,5-b]indoles (XI) such as the compound of EXAMPLE 13 which are useful in treating depression, obesity and other CNS disorders.
    Type: Application
    Filed: October 30, 2001
    Publication date: September 12, 2002
    Applicant: Pharmacia & Upjohn Company
    Inventors: Eric Jon Jacobsen, Susan Fax Jacobsen
  • Publication number: 20020128173
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Application
    Filed: January 4, 2002
    Publication date: September 12, 2002
    Applicant: Pharmacia & Upjohn Company
    Inventors: Erik H.F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson, Pasquale Cetera
  • Patent number: 6448258
    Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of heterocyclic amine-type compounds or a salt of any said compound.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: September 10, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley
  • Patent number: 6448397
    Abstract: The present invention provides oxazinocarbazole derivatives having a ring connecting position 8 (C-8) and position 9 (N-9), and more specifically, provides compounds of formula (I) wherein R1, R2, R3 and R4 are described herein. These compounds are 5-HT ligands, and are useful for treating diseases wherein modulation of 5-HT activity is desired.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: September 10, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventor: Ruth Elizabeth TenBrink
  • Patent number: 6444813
    Abstract: The invention is a process to produce a compound, linezolid which is useful as an antibacterial agent.
    Type: Grant
    Filed: January 29, 2001
    Date of Patent: September 3, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventor: Michael S. Bergren
  • Patent number: 6441005
    Abstract: Oxazolidinones and methods for their synthesis are provided. Further provided are methods of making biologically active oxazolidinones as well as pharmaceutically acceptable compositions comprising the oxazolidinones. Oxazolidinones as disclosed herein can be readily synthesized and used in a variety of applications including use as antimicrobial agents. In one embodiment, a variety of thioamidomethyloxazolidinones and methods for their synthesis and use are provided.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: August 27, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mikhail F. Gordeev, Gary W. Luehr, Dinesh V. Patel, Robert C. Gadwood